Revised Rules of Procedure of the Monitoring Group of the Anti-Doping Convention / Monitoring Group of the Anti-Doping Convention. - Strasbourg : Council of Europe (CoE), 2015
iNADO Update (2019) 8 (28 August)
Institute of National Anti-Doping Organisations (iNADO)
Contents:
- iNADO Board Chair Michael Ask on the future of iNADO and WADA
- Conference Call with WADA
- iNADO CEO Forum Katowice (Nov. 4)
- World Conference on Doping: Registration closes August 30
- Vacancies at the French Anti-Doping Agency
- AMADA offers Athletes a Pro Bono Legal Aid Mechanism
- Athletes Belief in Supplements is undeserved. Recent cases in Australia and Canada
- The Prevalence of Maltreatment in Sport among Top Canadian Athletes
- Brendan Schwab (World Players Association) explains Athletes Protests
- First Report on Testing for Tramadol in Cycling
- IO Reports: Major Event Organisers should store Samples for longer
- Evaluating Anti-Doping Programmes of National Federations
- International Conference on Fitness Doping and Public Health (24-25 Oct., Copenhagen)
- Berlinger: BEREG-Kit celebrates 25 years and New Head of Marketing and Sales
- New at the Anti-Doping Knowledge Center
Results of the WADA monitoring program regarding substances which are not on the 2018 Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.
These substances are:
In Competition Monitoring:
- Tramadol
- Codeine
- Hydrocodone
In and Out of Competition Monitoring:
- Beta-2 Agonists
- Bemitil
- Glucocorticoids
Annual banned-substance review: Analytical approaches in human sports drug testing / Mario Thevis, Tiia Kuuranne, Hans Geyer. - (Drug Testing and Analysis 11 (2019) 1 (January; p. 8-26)
Contents:
Abstract
A number of high profile revelations concerning anti‐doping rule violations over the past 12 months have outlined the importance of tackling prevailing challenges and reducing the limitations of the current anti‐doping system. At this time, the necessity to enhance, expand, and improve analytical test methods in response to the substances outlined in the World Anti‐Doping Agency (WADA) Prohibited List represents an increasingly crucial task for modern sports drug testing programs. The ability to improve analytical testing methods often relies on the expedient application of novel information regarding superior target analytes for sports drug testing assays, drug elimination profiles, and alternative sample matrices, together with recent advances in instrumental developments. This annual banned‐substance review evaluates literature published between October 2017 and September 2018 offering an in‐depth evaluation of developments in these arenas and their potential application to substances reported in WADA's 2018 Prohibited List.
In March 2017 World Rugby has reported an anti-doping rule violation against the rugby player Adrian Gabriel Chiper after his sample tested positive for the prohibited substance 19-norandrosterone (Nandrolone). After notification a provisional suspension was ordered. The Athlete filed a statement in his defence and he was heard for the World Rugby Judicial Committee.
The Athlete admitted the violation, denied the intentional use and was unaware that there was anti-doping information on the internet neither that steroids were prohibited. He stated that he had purchased the substance as medication on the internet as treatment for his knee injury. He acknowledged that he didn’t report his injury to the team officials and failed to mention his medication on the Doping Control Form. He only discussed his medication with his team doctor after de sample collection.
World Rugby contended that the Athlete failed to demonstrate that the violation was not intentional nor how the substance entered his system. It requested the Committee for the imposition of a 4 year period of ineligibility.
On the balance of probabilities, the Judicial Committee is skeptical about the Athlete’s statement. The Committee holds that to self-diagnose and to self-treat a knee injury in the sport of rugby, based on advice from Google, is difficult to understand. The Committee finds it difficult to accept the Athlete’s version how the prohibited substance entered his system. While not absolutely essential to proving that the violation was unintentional, any question about the source of the prohibited substance severely undercuts the Athlete’s case on this point.
Therefore the World Rugby Judicial Committee decides on 20 August 2018 to impose a 4 year period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 10 November 2017.
Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma : A Narrative Review and Critical Appraisal of Current Regulations / Hayden Allen, Susan H. Backhouse, James H. Hull, Oliver J. Price . - (Sports Medicine (2019) 18 March; p. 1-10).
- PMID: 30887312.
- DOI: 10.1007/s40279-019-01075-z
Abstract
Asthma is prevalent in athletes and when untreated can impact both respiratory health and sports performance. Pharmacological inhaler therapy currently forms the mainstay of treatment; however, for elite athletes competing under the constraints of the World Anti-Doping Code (Code), a number of established therapies are prohibited both in and/or out of competition and/or have a maximum permitted dose. The recent release of medical information detailing inhaler therapy in high-profile athletes has brought the legitimacy and utilisation of asthma medication in this setting into sharp focus. This narrative review critically appraises recent changes to anti-doping policy and the Code in the context of asthma management, evaluates the impact of asthma medication use on sports performance and employs a theory of behaviour to examine perceived determinants and barriers to athletes adhering to the anti-doping rules of sport when applied to asthma.
Report of the Independent Observers XVIII Asian Games Jakarta Palembang 2018 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2019
Impact of anti-doping education and doping control experience on anti-doping knowledge in Japanese university athletes: a cross-sectional study / Yuka Murofushi, Yujiro Kawata, Akari Kamimura, Masataka Hirosawa, Nobuto Shibata. - (Substance abuse treatment, prevention, and policy 13 (2018) 44 (5 Dec); p. 1-15).
- PMID: 30518383.
- PMCID: PMC6280366.
- DOI: 10.1186/s13011-018-0178-x
Abstract:
BACKGROUND:
This study was conducted to elucidate the anti-doping (AD) education, doping control experience, and AD knowledge according to the World Anti-doping Code (Code) of Japanese university athletes.
METHODS:
We collected data from 514 male athletes (Mage = 19.53 years, SD = 1.13) and 629 female athletes (Mage = 20.99 years, SD = 1.07). We asked them about their experience undergoing doping control and the AD education they had received. Then, we assessed their AD knowledge using the World Anti-Doping Agency's Athlete Learning Program about Health and AD (ALPHA) test.
RESULTS:
The results showed that 2.54% of the participants had undergone doping control. Further, 30.10% received AD education at least once, and 20.82% received AD education more than once. When comparing the ALPHA scores of athletes with/without doping test experience, we observed no significant difference. However, the ALPHA scores of athletes with/without AD education were significantly different; specifically, athletes who received AD education more than once had significantly higher ALPHA scores than non-educated athletes.
CONCLUSION:
These results revealed that doping control experience was not related to AD knowledge and that AD education was associated with AD knowledge, suggesting that athletes who receive AD education more than once have more accurate AD knowledge than less educated athletes on this topic. The importance of AD education in promoting understanding of AD according to the Code in sports is highlighted in this study.
